Exact Sciences hits a home run
The company presented more data supporting their non-invasive screening test for early stage and pre-cancerous lesions for colorectal cancer.
Here is today's 8k: http://files.shareholder.com/downloads/EXAS/1512445218x0xS1104659-11-64511/1124140/1104659-11-64511.pdf
I've said it once, I'll say it again, this is a cheap stock ($8s right now) given its potential. I think it will go over $20 within 2 years and then become a take-out target at a significant premium to the $20 something price. JMHO.